Drugs / PEG-Tα1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02366208 | May 2011 → Jun 2013 | chronic hepatitis B virus infection | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02366247 | Aug 2013 → Dec 2015 | chronic hepatitis B virus infection | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-Tα1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02366247 ↗ |
| Known as | Polyethylene Glycol thymosin alpha1 | “This trial is to assess the efficacy and safety of Polyethylene Glycol thymosin alpha1 (PEG-Tα1), a new long immunomodulator (Category 1.1 of Chemical Drugs) being developed...” NCT02366247 ↗1“Polyethylene Glycol thymosin alpha1 (PEG-Tα1), a new long immunomodulator” NCT02366208 ↗ |
| Route | Subcutaneous | “taken subcutaneously” NCT02366208 ↗ |